{"id":"arterakine-dha-piperaquine","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dihydroartemisinin acts rapidly by generating reactive oxygen species that damage parasite membranes and proteins, while piperaquine provides prolonged antimalarial activity by inhibiting parasite heme polymerization. The combination leverages the speed of artemisinin derivatives with the sustained efficacy of quinolines, reducing treatment duration and improving cure rates while minimizing resistance development.","oneSentence":"Arterakine combines dihydroartemisinin (a fast-acting artemisinin derivative) with piperaquine (a long-acting quinoline) to kill malaria parasites through multiple mechanisms including rapid parasite clearance and sustained suppression.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:42:37.713Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria caused by Plasmodium falciparum"},{"name":"Uncomplicated malaria caused by Plasmodium vivax"}]},"trialDetails":[{"nctId":"NCT02788864","phase":"PHASE4","title":"Prevention of Malaria With Dihydroartemisinine + Piperaquine for Forest Rangers","status":"COMPLETED","sponsor":"Oxford University Clinical Research Unit, Vietnam","startDate":"2016-05-20","conditions":"Malaria","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Arterakine (DHA/piperaquine)","genericName":"Arterakine (DHA/piperaquine)","companyName":"Oxford University Clinical Research Unit, Vietnam","companyId":"oxford-university-clinical-research-unit-vietnam","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Arterakine combines dihydroartemisinin (a fast-acting artemisinin derivative) with piperaquine (a long-acting quinoline) to kill malaria parasites through multiple mechanisms including rapid parasite clearance and sustained suppression. Used for Uncomplicated malaria caused by Plasmodium falciparum, Uncomplicated malaria caused by Plasmodium vivax.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}